GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
M

Maccura Biotechnology Co 300463.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

8.96

-1.10%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Maccura Biotechnology Co

Its shares trade on Shenzhen under the ticker 300463.SZ. It has been listed since 28 May 2015. In the fiscal year to 31 December 2025, it reported revenue of CN¥2.17bn and a net loss of CN¥35.8m. At that date it held total assets of CN¥7.99bn and shareholders' equity of CN¥6.28bn.

Maccura Biotechnology Co., Ltd. engages in the research, development, production, sale, and service of in vitro diagnostic products. The company is headquartered in Chengdu, Sichuan. The company went IPO on 2015-05-28. The firm provides hundreds of products which cover clinical biochemistry, chemiluminescent immunoassay, rapid diagnosis, thrombosis, hemostasis, and molecular diagnosis.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Life Sciences Tools & Services
Listed since
28 May 2015
Employees
3,016
Website
maccura.com ↗

Leadership

Pay as last reported

  • Mr. Yong TangChairman of the Board, since 2017CN¥1.4m
  • Ms. Shan YinFinance Director, Director, since 2021CN¥817,900
  • Mr. Xin LinChief Human Resources Officer
  • Ms. Ping YuChief Administrative OfficerCN¥717,400
  • Ms. Wei ShiChief Strategic Investment Officer, Secretary of the BoardCN¥762,700
  • Mr. Mingjian WuGeneral Manager, Director, since 2017CN¥1.2m
  • Ms. Hong DengChief Quality Officer, Director, since 2025
  • Mr. Dengming WangChief Business Officer, Director, since 2023CN¥712,500
  • Mr. Tengxiang LongChief Research and Development Officer (Reagents)CN¥965,700
  • Mr. Weijia WangChief Research and Development Officer (Instruments)CN¥952,400
  • Mr. Zhen WangChief Production Officer (Instruments)CN¥702,800
  • Mr. Qilin LiuDirector, since 2021CN¥643,500

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
71
Environment
71
Social
99
Governance
43
Direct emissions (scope 1)
582.07 t
Energy emissions (scope 2)
8,913.73 t
Women in the workforce
39.9%
Carbon reduction policy
Yes
Human rights policy
Yes

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Company employs 3016 full-time employees
  • Offers hundreds of in vitro diagnostic products
  • Headquartered in Chengdu, Sichuan

Weaknesses

  • No specific weaknesses mentioned in provided data
  • No financial performance data provided
  • No market share or competitive position details

Opportunities

  • Growth potential in Life Sciences Tools & Services sector
  • Expansion of product offerings in clinical biochemistry and molecular diagnosis
  • Potential for increased market presence in China

Threats

  • No specific threats mentioned in provided data
  • No competitive analysis provided
  • No regulatory challenges mentioned

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.